[
  {
    "ts": null,
    "headline": "Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug",
    "summary": "Merck (MRK) recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event that coincides with the company's 4.98% share price increase last month. Positive outcomes from the CORALreef Lipids trial and new approvals in various treatments underscore Merck's commitment to advancing its portfolio in oncology and cardiovascular diseases. This aligns with a broadly positive market context where major...",
    "url": "https://finnhub.io/api/news?id=ca10860f16f4c9a978f824b09ade8a1b940107e088d6e078702c5a8928c36f3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757356089,
      "headline": "Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug",
      "id": 136688962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event that coincides with the company's 4.98% share price increase last month. Positive outcomes from the CORALreef Lipids trial and new approvals in various treatments underscore Merck's commitment to advancing its portfolio in oncology and cardiovascular diseases. This aligns with a broadly positive market context where major...",
      "url": "https://finnhub.io/api/news?id=ca10860f16f4c9a978f824b09ade8a1b940107e088d6e078702c5a8928c36f3e"
    }
  },
  {
    "ts": null,
    "headline": "Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy",
    "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of spevatamig in combination with chemotherapy for the treatment of biliary tract carcinoma (BTC).",
    "url": "https://finnhub.io/api/news?id=5a280ffad162898bc13251fae2c44e7a8bf850a4df241656818fa120edb6d725",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757355480,
      "headline": "Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy",
      "id": 136688963,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of spevatamig in combination with chemotherapy for the treatment of biliary tract carcinoma (BTC).",
      "url": "https://finnhub.io/api/news?id=5a280ffad162898bc13251fae2c44e7a8bf850a4df241656818fa120edb6d725"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript",
    "summary": "Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript",
    "url": "https://finnhub.io/api/news?id=aea5adfc27197020dee07a095d1d82f24ec56a50fb73739007cacfe6baccfad6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757351767,
      "headline": "Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript",
      "id": 136672491,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=aea5adfc27197020dee07a095d1d82f24ec56a50fb73739007cacfe6baccfad6"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch",
    "summary": "Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch",
    "url": "https://finnhub.io/api/news?id=f891b5d72c1cc301739b209697ca91d9b9a8eb8f3babef184d868e0e239ce5ef",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757347739,
      "headline": "Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch",
      "id": 136713826,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch",
      "url": "https://finnhub.io/api/news?id=f891b5d72c1cc301739b209697ca91d9b9a8eb8f3babef184d868e0e239ce5ef"
    }
  },
  {
    "ts": null,
    "headline": "J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?",
    "summary": "ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.",
    "url": "https://finnhub.io/api/news?id=3ce7ff8fd165f8dfca9e5195db735cd7ffcd2b1bd13bb4fb0bd0d0b7eeebcf04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757340900,
      "headline": "J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?",
      "id": 136674234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.",
      "url": "https://finnhub.io/api/news?id=3ce7ff8fd165f8dfca9e5195db735cd7ffcd2b1bd13bb4fb0bd0d0b7eeebcf04"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences",
    "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC). The trial included patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). Ivonescimab is considered a rival to",
    "url": "https://finnhub.io/api/news?id=81aafc7e1fe0cda2fa92e89d98992da4d5b1f65bfe38279f51f21c92c2071a02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757338087,
      "headline": "Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences",
      "id": 136669249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC). The trial included patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). Ivonescimab is considered a rival to",
      "url": "https://finnhub.io/api/news?id=81aafc7e1fe0cda2fa92e89d98992da4d5b1f65bfe38279f51f21c92c2071a02"
    }
  },
  {
    "ts": null,
    "headline": "Top Dividend Stocks To Consider In September 2025",
    "summary": "As U.S. markets experience fluctuations following recent record highs and the anticipation of a Federal Reserve rate cut, investors are closely monitoring dividend stocks for their potential to provide steady income amidst economic uncertainty. In this environment, selecting dividend stocks with strong fundamentals and consistent payout histories can offer stability and resilience in an ever-changing market landscape.",
    "url": "https://finnhub.io/api/news?id=0f57fe443974535f5d1d767a026fe66425a1917d69351e7971b06261582b9046",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757334713,
      "headline": "Top Dividend Stocks To Consider In September 2025",
      "id": 136669168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As U.S. markets experience fluctuations following recent record highs and the anticipation of a Federal Reserve rate cut, investors are closely monitoring dividend stocks for their potential to provide steady income amidst economic uncertainty. In this environment, selecting dividend stocks with strong fundamentals and consistent payout histories can offer stability and resilience in an ever-changing market landscape.",
      "url": "https://finnhub.io/api/news?id=0f57fe443974535f5d1d767a026fe66425a1917d69351e7971b06261582b9046"
    }
  },
  {
    "ts": null,
    "headline": "Summit shares tumble on mixed data for lung cancer drug",
    "summary": "Summit Therapeutics shares dropped 14% on Monday following mixed results from a longer-term follow-up of North American and European patients in its late-stage lung cancer drug trial.  The study results, reported on Sunday, showed that the drug, ivonescimab, had stronger benefit in patients with non-small cell lung cancer (NSCLC) in China, compared with patients in the other two regions.  While the study continues to read positively in aggregate, the details on the Asian vs. non-Asian subgroups were worse than expected, said Piper Sandler analyst Kelsey Goodwin.",
    "url": "https://finnhub.io/api/news?id=1e6a404538107462c9463f92df7e961f6ac8e1405caab4aba7c5d0801bbcc14f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757334614,
      "headline": "Summit shares tumble on mixed data for lung cancer drug",
      "id": 136669251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics shares dropped 14% on Monday following mixed results from a longer-term follow-up of North American and European patients in its late-stage lung cancer drug trial.  The study results, reported on Sunday, showed that the drug, ivonescimab, had stronger benefit in patients with non-small cell lung cancer (NSCLC) in China, compared with patients in the other two regions.  While the study continues to read positively in aggregate, the details on the Asian vs. non-Asian subgroups were worse than expected, said Piper Sandler analyst Kelsey Goodwin.",
      "url": "https://finnhub.io/api/news?id=1e6a404538107462c9463f92df7e961f6ac8e1405caab4aba7c5d0801bbcc14f"
    }
  },
  {
    "ts": null,
    "headline": "Verizon, Merck share losses contribute to Dow's 118-point drop",
    "summary": "Verizon, Merck share losses contribute to Dow's 118-point drop",
    "url": "https://finnhub.io/api/news?id=b7af68cac5c2809cc362ea9c0d7f1aadd91aa495b69ee0d525e3b966d9fdf5df",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757324700,
      "headline": "Verizon, Merck share losses contribute to Dow's 118-point drop",
      "id": 136713848,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Verizon, Merck share losses contribute to Dow's 118-point drop",
      "url": "https://finnhub.io/api/news?id=b7af68cac5c2809cc362ea9c0d7f1aadd91aa495b69ee0d525e3b966d9fdf5df"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
    "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
    "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757316643,
      "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
      "id": 136668317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196154167/image_2196154167.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
      "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4"
    }
  }
]